Professional Chiropractic, Inc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 245 Blue Hill Ave, Roxbury, MA 02119 Phone: 617-989-8881 Fax: 617-989-8810 |
Dba Chiorpractic Health Center Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 1441 Tremont St., Chiropractic Health Center, Roxbury, MA 02120 Phone: 617-708-1227 Fax: 617-708-1253 |
Wallace K Massah, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 190 Dudley St, Roxbury, MA 02119 Phone: 617-442-8600 |
Dr. Pierre Daniel Abdilmasih, D.C. Chiropractor - Nutrition Medicare: Not Enrolled in Medicare Practice Location: 245 Blue Hill Ave, Roxbury, MA 02119 Phone: 617-989-8881 |
Boston Community Chiropractic Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 190 Dudley, Roxbury, MA 02119 Phone: 617-442-8600 Fax: 617-442-8655 |
News Archive
GI Partners ("GI"), a leading mid-market private equity firm, announced today the sale of its portfolio company, Plum Healthcare Group, LLC ("Plum"), one of the fastest growing companies in healthcare services, to Bay Bridge Capital Partners ("Bay Bridge"). The sale of Plum generated a return of approximately three times invested capital for limited partners in GI Partners Fund II L.P.
Although only one in 10 American adults eats enough fruits and vegetables, new research being presented at the Experimental Biology meeting this week in Washington, D.C., finds older adults are consuming higher levels of carotenoids, flavonoids and other phytonutrients found in fruits and vegetables that are thought to support healthy aging.
Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2010 and provided an update on its corporate developments.
Roswell Park Cancer Institute (RPCI) faculty members recently met with the Hungarian Health Minister and other government officials to discuss strategies to reduce smoking in Hungary.
Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.
› Verified 2 days ago